Tamoxifen
- Generic Name
- Tamoxifen
- Brand Names
- Soltamox
- Drug Type
- Small Molecule
- Chemical Formula
- C26H29NO
- CAS Number
- 10540-29-1
- Unique Ingredient Identifier
- 094ZI81Y45
- Background
Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations. Tamoxifen is used alone or as an adjuvant in these treatments. Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, s...
- Indication
Tamoxifen is indicated to treat estrogen receptor positive metastatic breast cancer in adults, as an adjuvant in the treatment of early stage estrogen receptor positive breast cancer in adults, to reduce the risk of invasive breast cancer after surgery and radiation in adult women with ductal carcinoma in situ.
- Associated Conditions
- Breast Cancer, Contralateral Breast Cancer, Desmoid Tumor, Early Stage Estrogen Receptor (ER) Positive Breast Cancer, Gynecomastia, Invasive Breast Cancer, Ovarian Cancer, Puberty, Precocious, Metastatic Estrogen Receptor Positive Breast Cancer
- Associated Therapies
- Ovulation induction therapy
Neoadjuvant Hormonal Therapy Compared to Neoadjuvant Chemotherapy in Stage IIIB/C and IV Breast Cancer Patients
- First Posted Date
- 2016-12-16
- Last Posted Date
- 2019-06-19
- Lead Sponsor
- Dharmais National Cancer Center Hospital
- Target Recruit Count
- 122
- Registration Number
- NCT02995772
- Locations
- 🇮🇩
Dharmais National Cancer Center Hospital, Jakarta, Indonesia
TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-12-12
- Last Posted Date
- 2021-09-22
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 28
- Registration Number
- NCT02988986
- Locations
- 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
🇺🇸Houston Methodist Hospital Willowbrook, Houston, Texas, United States
🇺🇸Houston Methodist Hospital Sugar Land, Sugar Land, Texas, United States
Impact of Low-dose Tamoxifen on BPU
- First Posted Date
- 2016-12-01
- Last Posted Date
- 2019-07-16
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 22
- Registration Number
- NCT02979301
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-11-22
- Last Posted Date
- 2019-07-12
- Lead Sponsor
- Evgen Pharma
- Target Recruit Count
- 60
- Registration Number
- NCT02970682
- Locations
- 🇧🇪
Grand Hopital de Charleroi, Service D'Oncologie-Hematologie, Charleroi, Belgium
🇧🇪Saint-Luc hospital, Brussels, Woluwe-Saint-Lambert, Belgium
🇫🇷ICO René Gauducheau, St Herblain, Nantes, Loire Atlantique, France
Examination of Breast Cancer Cells of Pre-menopausal and Post-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant.
- First Posted Date
- 2016-10-18
- Last Posted Date
- 2021-05-19
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 2
- Registration Number
- NCT02936206
- Locations
- 🇺🇸
Mount Sinai West, New York, New York, United States
🇺🇸Mount Sinai St. Luke's, New York, New York, United States
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen in Young Women
- Conditions
- Interventions
- First Posted Date
- 2016-09-26
- Last Posted Date
- 2023-01-17
- Target Recruit Count
- 680
- Registration Number
- NCT02914158
- Locations
- 🇨🇳
Guangdong People's Hospital, Guangzhou, China
🇨🇳Guangzhou First Municipal People's Hospital, Guangzhou, China
🇨🇳Maoming People's Hospital, Maoming, China
Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib
- Conditions
- Interventions
- First Posted Date
- 2016-09-23
- Last Posted Date
- 2021-07-26
- Lead Sponsor
- Shannon Puhalla
- Target Recruit Count
- 7
- Registration Number
- NCT02913430
- Locations
- 🇺🇸
Magee-Womens Hospital UPMC, Pittsburgh, Pennsylvania, United States
Treatment of Unfavorable Bleeding Patterns in Contraceptive Implant Users
- Conditions
- Interventions
- First Posted Date
- 2016-09-16
- Last Posted Date
- 2020-07-15
- Lead Sponsor
- Oregon Health and Science University
- Target Recruit Count
- 109
- Registration Number
- NCT02903121
- Locations
- 🇺🇸
OHSU, Portland, Oregon, United States
Evaluation of the Efficacy of Estramustine in Patient With Breast Cancer Progression After Treatment With Aromatase Inhibitor.
- First Posted Date
- 2016-08-15
- Last Posted Date
- 2020-03-09
- Lead Sponsor
- Institut de Cancérologie de Lorraine
- Target Recruit Count
- 100
- Registration Number
- NCT02866955
- Locations
- 🇫🇷
Institut Sainte Catherine, Avignon, France
🇫🇷Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France
🇫🇷CHU Besançon-Jean Minjoz, Besançon, France
Treatment Effect of Tamoxifen on Patients With DMD
- First Posted Date
- 2016-07-15
- Last Posted Date
- 2022-07-25
- Lead Sponsor
- Hadassah Medical Organization
- Target Recruit Count
- 19
- Registration Number
- NCT02835079
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.